로딩 중…
지수 로딩 중…
Neurogene Inc.
NGNE· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$27.57-4.34%
2026-10-30
Financials
Valuation Metrics
Neurogene Inc.'s Market Cap is $552M. At end of 2025 it was $436M. Ranked #2695 of 3,116 in US market (top 86%), #1166 of 1,472 on NASDAQ (top 79%), #212 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 80%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $552M | US#2,695/3,116 Sec#212/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-111M | US—/3,116 Sec—/265 |
| Total Assets | $244M | US#2,947/3,116 Sec#231/265 |
| Net Assets | $217M | US#2,645/3,116 Sec#184/265 |
| Employees | 131 | US#2,566/3,116 Sec#158/265 |
| Value | ||
| P/B | 2.54x | US#1,616/3,116 Sec#82/265 |
| FCF Yield | -15.79% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -51.17% | US#2,677/3,116 Sec#158/265 |
| ROA | -45.47% | US#2,966/3,116 Sec#202/265 |
| Financial Health | ||
| Debt Ratio | 12.54% | US#140/3,116 Sec#58/265 |
| Total Debt | $8M | US#2,845/3,116 Sec#203/265 |
| FCF | $-87M | US#2,615/3,116 Sec#136/265 |
| Cash | $112M | US#2,149/3,116 Sec#162/265 |
| Current Ratio | 10.64x | US#227/3,116 Sec#71/265 |
| Performance | ||
| 1Y Return | -16.81% | US#2,192/3,116 Sec#178/265 |
| 1M Return | -0.90% | US#1,684/3,116 Sec#112/265 |
| From 52W High | -36.85% | US#2,177/3,116 Sec#148/265 |
| 1Y MDD | -49.67% | US#2,490/3,116 Sec#175/265 |
| Trading | ||
| Volume | 206,837 shares | US#2,500/3,116 Sec#238/265 |
| Trading Value | $6M | US#2,443/3,116 Sec#202/265 |
| Per Share | ||
| EPS | $-5.55 | US—/3,116 Sec—/265 |
| BPS | $10.85 | US#1,781/3,116 Sec#67/265 |
Company Info
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.